DBV Technologies报告过敏治疗研究的长期安全和有效性。 DBV Technologies reports long-term safety and effectiveness in allergy treatment study.

DBV Technologies宣布了对其过敏治疗方法进行三年期研究的积极结果。 DBV Technologies has announced positive results from a three-year study on their allergy treatment method. EPITOPE第3阶段研究是一个开放标签的延伸,表明长期治疗是安全和有效的。 The EPITOPE Phase 3 study is an open-label extension that suggests the treatment is safe and effective over a long period. 对于食品过敏者来说,这是一个好消息,因为它表明治疗持续带来益处。 This is good news for those with food allergies, as it indicates sustained benefits from the therapy.